Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | CTSG | P08311 | 1/20 | 0.59 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.59 |
| ▸ | CMA1 | P23946 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11793652 | 0.98 | GAA (0.61) | GAASMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL6170086 | 0.88 | NPC1 (0.66) | GAASMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL3192014 | 0.87 | LMNA (0.77) | GAASMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL9861012 | 0.86 | HDAC1 (0.72) | GAASMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL9491686 | 0.83 | NPC1 (0.75) | GAASMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL8779817 | 0.83 | HDAC1 (0.79) | GAASMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL2588306 | 0.83 | GAA (0.68) | GAASMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL18689914 | 0.81 | LMNA (0.69) | GAASMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL20734829 | 0.81 | HDAC1 (0.82) | GAASMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL604217 | 0.81 | GAA (0.65) | GAASMN1; SMN2LMNAPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063205-B2 | Method for producing 2-oxazoline analogue or 1,3-oxazine analogue | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1956012-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | National University Corporation Hokkaido University (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-0292006-B1 | AMINOETHYLCYSTEINE DERIVATIVES | Sanraku Incorporated (JP) | 1991-08-21 | — | — | EP | disclosed |
| US-4853407-A | Aminoethylcysteine derivatives | SANRAKU INCORPORATED (JP) | 1989-08-01 | — | — | US | disclosed |
| EP-0292006-A1 | Aminoethylcysteine derivatives | Sanraku Incorporated (JP) | 1988-11-23 | — | — | EP | disclosed |
| EP-0151449-B1 | PROCESS FOR THE PRODUCTION OF FLUORINE CONTAINING N-(BETA-BROMOETHYL)AMIDE AND OF 2-(PERFLUOROALKYL)-1,3-OXAZOLINE | ASAHI GLASS COMPANY LTD. (JP) | 1988-04-20 | — | — | EP | disclosed |
| EP-0104614-B1 | PHENYLPIPERAZINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 1986-12-30 | — | — | EP | disclosed |
| US-4560686-A | Method for treating circulatory diseases by using (2-lower alkoxyphenyl)piperazine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1985-12-24 | — | — | US | disclosed |
| EP-0090063-B1 | PROCESS FOR MAKING N-(2-AMINOETHYL)AMIDES FROM OXAZOLINES AND AMINES | THE DOW CHEMICAL COMPANY (US) | 1985-09-11 | — | — | EP | disclosed |
| EP-0151449-A2 | Process for the production of fluorine containing N-(beta-bromoethyl)amide and of 2-(perfluoroalkyl)-1,3-oxazoline | ASAHI GLASS COMPANY LTD. (JP) | 1985-08-14 | — | — | EP | disclosed |
| EP-0090063-A1 | Process for making N-(2-aminoethyl)amides from oxazolines and amines | THE DOW CHEMICAL COMPANY (US) | 1983-10-05 | — | — | EP | disclosed |
| US-4326067-A | FROM OXAZOLINE WITH AN AMINE | THE DOW CHEMICAL COMPANY (US) | 1982-04-20 | — | — | US | disclosed |
| US-3988341-A | Esterification process | MERCK & CO., INC. (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | OXA1L, SULT1A1, DAO | GAA 4358/4885SMN1; SMN2 3368/4885LMNA 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.